17 May 2016 - Bristol-Myers Squibb today announced the U.S. FDA has approved Opdivo (nivolumab) for the treatment of patients with classical Hodgkin's lymphoma who have relapsed or progressed after autologous hematopoietic stem cell transplantation and post-transplantation brentuximab vedotin.

This accelerated approval is based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

For more details, go to: http://news.bms.com/press-release/cancer/opdivo-nivolumab-granted-first-approval-pd-1-inhibitor-hematology-treatment-cla